JPMorgan warned of a recession in the U.S. after disclosing that it now expects real gross domestic product to contract under the weight of President Trump's tariffs. The bank's chief U.S ...

JPMorgan downgraded Dominion (D) to Underweight from Neutral with a price target of $52, down from $59. The firm sees “growing project risk on uncontrollable external factors” for the company ...

JPMorgan analysts told clients that Trump's tariff plan will have drastic economic effects. The risk of the global economy falling into a recession has increased from 40% to 60%, they warned. The ...

Autonomous reinstated coverage of JPMorgan (JPM) with a Neutral rating and $267 price target Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top ...

JPMorgan Chase CEO Jamie Dimon said Monday in a letter to shareholders that President Donald Trump's tariffs are likely to "increase inflation" on both foreign and domestic goods, and raised ...

Max, formerly known as HBO Max, officially has a new logo on Sunday night, March 30. The new logo for Warner Bros. Discovery's steaming platform was unveiled on Sunday evening. The new logo gives ...

Employees are waiting to hear how JPMorgan Chase will enforce its return-to-office mandate. They're searching for clues, in one instance sharing a leaked document in a group chat. Employees also ...

JPMorgan has raised its likelihood of the US economy entering a recession before the end of the year to 60% as President Donald Trump’s tariff plans upend markets worldwide. The nation’s ...

JPMorgan reported broad-based strength in Q4, with strong performance across investment banking, trading, and consumer segments, delivering $14B in net income and a 21% ROTCE. Analysts issued 10 ...

JPMorgan Chase & Co. said it expects the US economy to fall into a recession this year after accounting for the likely impact of tariffs announced this week by the Trump administration. “We now ...

A group of current and former employees of JPMorgan Chase (NYSE:JPM) has filed a lawsuit alleging that the company, through its prescription drug plan run by CVS Health (NYSE:CVS), overpaid for ...